Industry / Germany
EMEA Approvals - Xarelto To Enter Lucrative Oral Anticoagulant Market
July 2008 | Industry NewsBayer Healthcare's oral anticoagulant, Xarelto (rivaroxaban), has been recommended for EU marketing authorisation by the European Medicine Agency (EMEA)'s Committee for Products for Human Use (CHMP) in the agency's monthly appraisal meeting for July 2008. European Commission (EC) approval - which is likely to follow in the next couple of months - would allow the product to be used for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery, pitching the product against rival Boehringer Ingelheim's recently approved Pradaxa (dabigatran
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
